Clinical Trial Update: Sodium-glucose Transporter Type 2 Inhibition in Anthracycline-related Cardiotoxicity [NA]

View source ↗

Summary

A clinical trial is evaluating whether sodium-glucose transporter 2 (SGLT2) inhibitors can mitigate anthracycline-related cardiotoxicity in breast cancer patien…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• SGLT2 inhibitor

Snippet

Sponsor: University of Aberdeen | Conditions: Breast Cancer | NA | Status: NOT_YET_RECRUITING